The limited-edition 4K Ultra HD combo ($39.99 retail) includes audio commentaries, retrospective and vintage interviews, ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...

HUNTSVILLE, Ala. (WAFF) - During a press conference held on Tuesday, pharmaceutical giant Eli Lilly announced that they will construct a $6 billion state-of-the-art pharmaceutical manufacturing plant ...

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

The stock recently reached beyond $1,000. Investors generally don't turn to pharmaceutical stocks with expectations of high growth in a short period of time. Instead, they scoop up these players for ...

Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Nov 21 (Reuters) - Eli Lilly (LLY.N), opens new tab hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse. A more ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...